日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer

一项针对 II 期和 III 期激素受体阳性、HER2 阴性乳腺癌患者的术前来曲唑、依维莫司和卡罗妥昔单抗治疗的 I/II 期研究

Vaklavas, Christos; Stringer-Reasor, Erica M; Elkhanany, Ahmed M; Ryan, Kevin J; Li, Yufeng; Theuer, Charles P; Acosta, Edward P; Wei, Shi; Yang, Eddy S; Grizzle, William E; Forero-Torres, Andres

Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial

内皮糖蛋白抑制剂TRC105联合或不联合贝伐珠单抗治疗贝伐珠单抗难治性胶质母细胞瘤(ENDOT):一项多中心II期试验

Ahluwalia, Manmeet S; Rogers, Lisa R; Chaudhary, Rekha; Newton, Herbert; Ozair, Ahmad; Khosla, Atulya A; Nixon, Andrew B; Adams, Bonne J; Seon, Ben K; Peereboom, David M; Theuer, Charles P

Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial

TRC105联合帕唑帕尼与单用帕唑帕尼治疗晚期血管肉瘤患者的疗效和安全性:一项随机临床试验

Jones, Robin L; Ravi, Vinod; Brohl, Andrew S; Chawla, Sant; Ganjoo, Kristen N; Italiano, Antoine; Attia, Steven; Burgess, Melissa A; Thornton, Katherine; Cranmer, Lee D; Cheang, Maggie Chon U; Liu, Lingyun; Robertson, Liz; Adams, Bonne; Theuer, Charles; Maki, Robert G

Identification of neuroblastoma cell lines with uncommon TAZ(+)/mesenchymal stromal cell phenotype with strong suppressive activity on natural killer cells.

鉴定具有罕见的 TAZ(+)/间充质基质细胞表型的神经母细胞瘤细胞系,该细胞系对自然杀伤细胞具有很强的抑制活性

Canzonetta Claudia, Pelosi Andrea, Di Matteo Sabina, Veneziani Irene, Tumino Nicola, Vacca Paola, Munari Enrico, Pezzullo Marco, Theuer Charles, De Vito Rita, Pistoia Vito, Tomao Luigi, Locatelli Franco, Moretta Lorenzo, Caruana Ignazio, Azzarone Bruno

Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)

晚期或转移性肾细胞癌患者中阿昔替尼联合 TRC105 与阿昔替尼单药治疗的临床结果和生物标志物分析 (TRAXAR)

Choueiri, Toni K; Zakharia, Yousef; Pal, Sumanta; Kocsis, Judit; Pachynski, Russell; Poprach, Alexandr; Nixon, Andrew B; Liu, Yingmiao; Starr, Mark; Lyu, Jing; Owzar, Kouros; deShazo, Mollie; Lara, Primo; Geczi, Lajos; Ho, Thai H; Walsh, Meghara; Adams, Bonne; Robertson, Liz; Darif, Mohamed; Theuer, Charles; Agarwal, Neeraj

An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma

一项开放标签的 Ib 期剂量递增研究,评估 TRC105(抗内皮糖蛋白抗体)联合阿昔替尼治疗转移性肾细胞癌患者的疗效

Choueiri, Toni K; Michaelson, M Dror; Posadas, Edwin M; Sonpavde, Guru P; McDermott, David F; Nixon, Andrew B; Liu, Yingmiao; Yuan, Zhenhua; Seon, Ben K; Walsh, Meghara; Jivani, Manoj A; Adams, Bonne J; Theuer, Charles P

In Vivo Tumor-Targeted Dual-Modality PET/Optical Imaging with a Yolk/Shell-Structured Silica Nanosystem

利用蛋黄/壳结构二氧化硅纳米系统进行体内肿瘤靶向双模态PET/光学成像

Shi, Sixiang; Chen, Feng; Goel, Shreya; Graves, Stephen A; Luo, Haiming; Theuer, Charles P; Engle, Jonathan W; Cai, Weibo

Targeting angiogenesis for radioimmunotherapy with a (177)Lu-labeled antibody

利用(177)Lu标记抗体靶向血管生成进行放射免疫治疗

Ehlerding, Emily B; Lacognata, Saige; Jiang, Dawei; Ferreira, Carolina A; Goel, Shreya; Hernandez, Reinier; Jeffery, Justin J; Theuer, Charles P; Cai, Weibo

(86/90)Y-Based Theranostics Targeting Angiogenesis in a Murine Breast Cancer Model

(86/90)Y靶向小鼠乳腺癌模型血管生成的诊疗一体化

Ehlerding, Emily B; Ferreira, Carolina A; Aluicio-Sarduy, Eduardo; Jiang, Dawei; Lee, Hye Jin; Theuer, Charles P; Engle, Jonathan W; Cai, Weibo

Engineering Intrinsically Zirconium-89 Radiolabeled Self-Destructing Mesoporous Silica Nanostructures for In Vivo Biodistribution and Tumor Targeting Studies

利用工程技术构建本征锆-89放射性标记的自毁介孔二氧化硅纳米结构,用于体内生物分布和肿瘤靶向研究

Goel, Shreya; Chen, Feng; Luan, Shijie; Valdovinos, Hector F; Shi, Sixiang; Graves, Stephen A; Ai, Fanrong; Barnhart, Todd E; Theuer, Charles P; Cai, Weibo